I do believe a few things: 1. They overpaid for MRS 2. They underdelivered in sales growth 3. They overpromised on acquisitions 4. They put out a carrot of a density FDA paper approval which never ever occurs 5. They talk of capitalising on COVID-19 opportunities and deliver ZILCH 6. They dilute existing holders at will and squander cash like no tomorrow
Investors need endless patience in this overpriced healthcare company.
